Clinical trials: Smoking Cigarette
Smoking Cessation, Tobacco Use Cessation
Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)
The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are to assess the: craving for cigarettes, nicotine withdrawal symptoms…
- Trial name
- NCT00387946
- Testing
- SSR591813L (dianicline)
- Where
- 2 sites in United States, Canada
- Volunteers
- 630 people
- Sponsor
- Sanofi
Smoking
Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.
The overall goal of the study is to evaluate if the ad libitum use of the Tobacco Heating System 2.2 (THS 2.2) for 5 days by adult healthy smokers results in a reduction in the levels of biomarkers of exposure (BoExp) for…
- Trial name
- NCT01959932
- Testing
- Tobacco Heating System (THS 2.2), Smoking abstinence (SA), Conventional cigarette (CC)
- Where
- Poland
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation
Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)
Surinabant is a new, potent and selective antagonist for the cannabinoid CB1 receptor, which might be clinically useful in the treatment of dependence to nicotine.
- Trial name
- NCT00432575
- Testing
- surinabant (SR147778)
- Where
- 8 sites in Belgium, France and 6 more
- Volunteers
- 810 people
- Sponsor
- Sanofi
Electronic Cigarette Use
Characterization of Product Use in Smokers Switching From Cigarettes to a RELX Electronic Nicotine Delivery System
The study will assess product use behaviors, biomarkers of exposure, subjective effects, and safety in smokers who switch to a RELX ENDS over 8-weeks.
- Trial name
- NCT04708106
- Testing
- RELX ENDS Tobacco Flavor, RELX ENDS Menthol Flavor, RELX ENDS Tobacco and Menthol Flavors
- Where
- 5 sites in United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Cheerain HK Limited
Healthy Volunteers
The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking
This will be a phase 1 randomized, double-blind, 2-period, 2-sequence crossover trial enrolling 6 healthy volunteers to assess the impact of IV-administered Bendavia on the endothelial dysfunction induced by a single cigarette.
- Trial name
- NCT01518985
- Testing
- Bendavia, Sterile saline (0.9%), Cigarette smoking
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Mighty Therapeutics, Inc.
Environmental Exposure
Real-Life Passive Exposure Assessment of IQOS
This study is a non-interventional observational study designed to assess the impact of passive exposure to IQOS environmental tobacco aerosol in Non-Smokers in a real-life restaurant setting.
- Trial name
- NCT03550989
- Testing
- Non-Exposure Event, Exposure Event
- Where
- Japan
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Electronic Cigarette Use, Tobacco Smoking
Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems
The purpose of this study is to estimate nicotine uptake and assess subjective effects during ad libitum use sessions of 4 flavors of JUUL ENDS (also referred to as nicotine salt pod system; NSPS) products (i.e., Virginia…
- Trial name
- NCT04123041
- Testing
- JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum
- Where
- 2 sites in United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
Nicotine Addiction, Cigarette Smoking
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
Three hundred-twenty (320) adult smokers of menthol or non-menthol combustible cigarettes will be recruited and randomly assigned to one of five groups (n=64/group), who will be asked to switch for 12 weeks to ad libitum use of…
- Trial name
- DUAL (NCT02870218)
- Testing
- Smoking research cigarettes with e-cigarette, Nicotine discrimination thresholds
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation
Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes
This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CC) to an e-cigarette.
- Trial name
- BuZonE (NCT04388319)
- Testing
- Zonisamide, Bupropion, Halo G6 e-cigarette
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking, Smoking Behaviors
CSD210903: A Study to Determine Subject Puffing Patterns of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in an Ambulatory Setting
This is a multi-center, open-label, parallel-cohort-study to evaluate the puffing patterns of healthy adult consumers of tobacco products switching from a usual brand (UB) combustible cigarette (CC) and/or a UB Heated Tobacco…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05307822
- Testing
- Non-combusted cigarette variant 42001401, Non-combusted cigarette variant 42001399, Non-combusted cigarette variant 40007386
- Where
- 7 sites in United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Tobacco
CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers
The purpose of this Actual Use Study (AUS) is to investigate how United States (US) adult tobacco consumers 21 to 60 years of age, inclusive, who are regular smokers (≥5 cigarettes/day on at least 20 of the past 30 days) will use…
- Trial name
- NCT05960305
- Testing
- P1213416, P1213422, P1213716
- Where
- 12 sites in United States
- Volunteers
- 1,845 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Tobacco Use
Pharmacokinetic and Subjective Effects of Heated Tobacco Products
This is a randomized, controlled, six-way crossover clinical study to characterize the nicotine PK (pharmacokinetic) and subjective effects of HTPs (Heated Tobacco Products) comprised of 2 menthol varieties and 2 tobacco flavor…
- Trial name
- NCT06356610
- Testing
- Product A, Product B, Product C
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Altria Client Services LLC
Smoking
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).
The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 Menthol (mTHS), a candidate Modified Risk Tobacco Product…
- Trial name
- NCT01967706
- Testing
- mTHS, mCC, NRT
- Where
- Japan
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Tobacco Use Disorder, Smoking
Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen in Reducing Cigarette Craving in Smokers
Study to determine the safety and effectiveness of Ariva® Silver Wintergreen lozenge on reducing craving for a cigarette in daily smokers.
- Trial name
- NCT01337830
- Testing
- Ariva® Silver Wintergreen, Silver Wintergreen
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Star Scientific, Inc
Vaping, E-Cig Use
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
- Trial name
- ORCA-V1 (NCT05431387)
- Testing
- cytisinicline, Behavioral support
- Where
- 5 sites in United States
- Volunteers
- 160 people
- Sponsor
- Achieve Life Sciences
Electronic Cigarette Use
Use Behavior, Nicotine Uptake, and Subjective Effects Comparison of Tobacco and Menthol e-Liquids by ENDS Consumers
This study is being conducted to evaluate the impact of within-flavor category (tobacco and menthol) differences in e-liquid flavors on product use behaviors, nicotine uptake, and subjective effects by current ENDS consumers when…
- Trial name
- NCT05134415
- Testing
- RELX ENDS Tobacco Flavor 1, RELX ENDS Tobacco Flavor 2, RELX ENDS Menthol Flavor 1
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cheerain HK Limited
Smoking
Clinical Study of Smoke-Break Liquid Cigarettes
The purpose of this study is to determine whether the Smoke-Break nicotine delivery device can help smokers quit smoking, while avoiding many of the side effects associated with other smoking cessation products.
- Trial name
- NCT00715871
- Testing
- Nicotine, Smoke-Break nicotine delivery device
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Smoke-Break, Inc.
Smoking
Exploratory THS 2.1 Biomarkers of Exposure Study
The goal of this exploratory study is to evaluate the effect of a candidate modified risk tobacco product (MRTP), THS 2.1, on selected biomarkers of exposure to harmful and potentially harmful smoke constituents (HPHCs), compared…
- Trial name
- ZRHX-EX-01 (NCT01780714)
- Testing
- Conventional cigarettes (CC), THS 2.1
- Where
- Poland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Periodontal Diseases, Chronic Periodontitis
Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome
The purpose of this study was to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using IQOS improves the response to periodontal therapy and the overall oral health status…
- Conditions
- Periodontal Diseases, Chronic Periodontitis, Periodontal Pocket, Tooth Mobility
- Trial name
- NCT03364751
- Testing
- IQOS, Cigarette
- Where
- 26 sites in Japan
- Volunteers
- 179 people
- Sponsor
- Philip Morris Products S.A.